{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T20:46:27Z","timestamp":1780433187226,"version":"3.54.1"},"reference-count":48,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T00:00:00Z","timestamp":1628467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Israel Institute for Biological Research","award":["SB-241"],"award-info":[{"award-number":["SB-241"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Botulinum neurotoxins (BoNTs) are the most poisonous substances in nature. Currently, the only therapy for botulism is antitoxin. This therapy suffers from several limitations and hence new therapeutic strategies are desired. One of the limitations in discovering BoNT inhibitors is the absence of an in vitro assay that correlates with toxin neutralization in vivo. In this work, a high-throughput screening assay for receptor-binding inhibitors against BoNT\/A was developed. The assay is composed of two chimeric proteins: a receptor-simulating protein, consisting of the fourth luminal loop of synaptic vesicle protein 2C fused to glutathione-S-transferase, and a toxin-simulating protein, consisting of the receptor-binding domain of BoNT\/A fused to beta-galactosidase. The assay was applied to screen the LOPAC1280 compound library. Seven selected compounds were evaluated in mice exposed to a lethal dose of BoNT\/A. The compound aurintricarboxylic acid (ATA) conferred 92% protection, whereas significant delayed time to death (p &lt; 0.005) was observed for three additional compounds. Remarkably, ATA was also fully protective in mice challenged with a lethal dose of BoNT\/E, which also uses the SV2 receptor. This study demonstrates that receptor-binding inhibitors have the potential to serve as next generation therapeutics for botulism, and therefore the assay developed may facilitate discovery of new anti-BoNT countermeasures.<\/jats:p>","DOI":"10.3390\/ijms22168577","type":"journal-article","created":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T21:41:46Z","timestamp":1628545306000},"page":"8577","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Small Molecule Receptor Binding Inhibitors with In Vivo Efficacy against Botulinum Neurotoxin Serotypes A and E"],"prefix":"10.3390","volume":"22","author":[{"given":"Alon","family":"Ben David","sequence":"first","affiliation":[{"name":"Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona 74100001, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Barnea","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona 74100001, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eran","family":"Diamant","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona 74100001, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyal","family":"Dor","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona 74100001, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arieh","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona 74100001, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amram","family":"Torgeman","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona 74100001, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3249-4901","authenticated-orcid":false,"given":"Ran","family":"Zichel","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona 74100001, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1128\/mr.46.1.86-94.1982","article-title":"Bacterial toxins: A table of lethal amounts","volume":"46","author":"Gill","year":"1982","journal-title":"Microbiol. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1124\/pr.116.012658","article-title":"Botulinum neurotoxins: Biology, pharmacology, and toxicology","volume":"69","author":"Pirazzini","year":"2017","journal-title":"Pharmacol. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/164_2019_342","article-title":"The Structure and Classification of Botulinum Toxins","volume":"263","author":"Dong","year":"2021","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1146\/annurev.biochem.051908.125345","article-title":"Botulinum neurotoxin a marvell of protein design","volume":"79","author":"Montal","year":"2010","journal-title":"Annu. Rev. Biochem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jama.285.8.1059","article-title":"Botulinum toxin as a biological weapon: Medical and public health managment","volume":"285","author":"Arnon","year":"2001","journal-title":"J. Am. Med. Assoc."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41598-019-57103-5","article-title":"Human antibodies neutralizing diphtheria toxin in vitro and in vivo","volume":"10","author":"Wenzel","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"32665","DOI":"10.1074\/jbc.M112.400473","article-title":"A novel mechanism for antibody-based anthrax toxin neutralization: Inhibition of prepore-to-pore conversion","volume":"287","author":"Mechaly","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"446","DOI":"10.4161\/mabs.27773","article-title":"Development of neutralizing scFv-Fc against botulinum neurotoxin A light chain from a macaque immune library","volume":"6","author":"Miethe","year":"2014","journal-title":"MAbs"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Rukkawattanakul, T., Sookrung, N., Seesuay, W., Onlamoon, N., Diraphat, P., Chaicumpa, W., and Indrawattana, N. (2017). Human scFvs That Counteract Bioactivities of Staphylococcus aureus TSST-1. Toxins, 9.","DOI":"10.3390\/toxins9020050"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Jenkins, T.P., Fryer, T., Dehli, R.I., Jurgensen, J.A., Fuglsang-Madsen, A., Fons, S., and Laustsen, A.H. (2019). Toxin Neutralization Using Alternative Binding Proteins. Toxins, 11.","DOI":"10.3390\/toxins11010053"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13036-018-0138-z","article-title":"Inhibition of bacterial toxin recognition of membrane components as an anti-virulence strategy","volume":"13","author":"Krueger","year":"2019","journal-title":"J. Biol. Eng."},{"key":"ref_12","first-page":"179","article-title":"Small-molecule inhibitors of ricin and Shiga toxins","volume":"357","author":"Wahome","year":"2012","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Rasseti-Escargueil, C., and Popoff, M.R. (2019). Antibodies and vaccines against botulinum toxins: Available measures and novel approaches. Toxins, 11.","DOI":"10.3390\/toxins11090528"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpeds.2017.12.002","article-title":"BabyBIG has BIG advantages for treatment of infant botulism","volume":"193","author":"Long","year":"2018","journal-title":"J. Pediatr."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Diamant, E., Pass, A., Rosen, O., Ben David, A., Torgeman, A., Barnea, A., Tal, A., Rosner, A., and Zichel, R. (2018). A Novel Rabbit Spirometry Model of Type E Botulism and Its Use for the Evaluation of Postsymptom Antitoxin Efficacy. Antimicrob. Agents Chemother., 62.","DOI":"10.1128\/AAC.02379-17"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1021\/acs.accounts.9b00261","article-title":"Strategies to Counteract Botulinum Neurotoxin A: Nature\u2019s Deadliest Biomolecule","volume":"52","author":"Lin","year":"2019","journal-title":"Acc. Chem. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.2174\/1568026616666160413135630","article-title":"Searching for Therapeutics Against Botulinum Neurotoxins: A True Challenge for Drug Discovery","volume":"16","author":"Duplantier","year":"2016","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"115659","DOI":"10.1016\/j.bmc.2020.115659","article-title":"Synthesis and activity of isoleucine sulfonamide derivatives as novel botulinum neurotoxin serotype A light chain inhibitors","volume":"28","author":"Thompson","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.bmc.2012.12.001","article-title":"Evaluation of adamantane hydroxamates as botulinum neurotoxin inhibitors: Synthesis, crystallography, modeling, kinetic and cellular based studies","volume":"21","author":"Silvaggi","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e00089-18","DOI":"10.1128\/mBio.00089-18","article-title":"The light chain defines the duration of action of botulinum toxin serotype A subtypes","volume":"9","author":"Pellet","year":"2018","journal-title":"mBio"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1123654","article-title":"SV2 is the protein receptor for botulinum neurotoxin A","volume":"312","author":"Dong","year":"2006","journal-title":"Science"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/j.febslet.2006.02.074","article-title":"The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves","volume":"580","author":"Mahrhold","year":"2006","journal-title":"FEBS Lett."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/infdis\/150.3.407","article-title":"Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E","volume":"150","author":"Hatheway","year":"1984","journal-title":"J. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.7883\/yoken1952.39.29","article-title":"A case report on human type B botulism","volume":"39","author":"Takahashi","year":"1986","journal-title":"Jpn. J. Med. Sci. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"794","DOI":"10.4161\/hv.9420","article-title":"Botulinum neurotoxin vaccines: Past history and recent developments","volume":"5","author":"Rusnak","year":"2009","journal-title":"Hum. Vaccines"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Rosen, O., Ozeri, E., Barnea, A., David, A.B., and Zichel, R. (2016). Development of an Innovative in Vitro Potency Assay for Anti-Botulinum Antitoxins. Toxins, 8.","DOI":"10.3390\/toxins8100276"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/0006-8993(93)90069-Y","article-title":"Effects of systemic administration of 6-hydroxydopamine, 6-hydroxydopa and 1-methyl-4-phenyl-1,2,3,6-tetrahydroxypyridine (MPTP) on tuberoinfundibular dopaminergic neurons in the rat","volume":"624","author":"Lin","year":"1993","journal-title":"Brain Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1124\/jpet.115.228130","article-title":"Protoporphyrin IX: The Good, the Bad, and the Ugly","volume":"356","author":"Sachar","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Pellett, S., Tepp, W.H., and Johnson, E.A. (2019). Critical Analysis of Neuronal Cell and the Mouse Bioassay for Detection of Botulinum Neurotoxins. Toxins, 11.","DOI":"10.3390\/toxins11120713"},{"key":"ref_30","first-page":"61","article-title":"Double receptor anchorage of botulinum neurotoxins accounts for their exquisite neurospecificity","volume":"364","author":"Rummel","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1021\/cc060010h","article-title":"Synthesis, characterization and development of a high-throughput methodology for the discovery of botulinum neurotoxin A inhibitors","volume":"8","author":"Boldt","year":"2006","journal-title":"J. Comb. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ab.2011.01.002","article-title":"Detection of six serotypes of botulinum neurotoxin using fluorogenic reporters","volume":"411","author":"Ruge","year":"2011","journal-title":"Anal. Biochem"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.toxicon.2017.06.016","article-title":"Small molecule metalloprotease inhibitor with in vitro, ex vivo and in vivo efficacy against botulinum neurotoxin serotype A","volume":"137","author":"Jacobson","year":"2017","journal-title":"Toxicon"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"E2253","DOI":"10.1073\/pnas.1616892114","article-title":"Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease","volume":"114","author":"Dunn","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","first-page":"853","article-title":"Inhibition of topoisomerase II by aurintricarboxylic acid: Implications for mechanisms of apoptosis","volume":"14","author":"Catchpoole","year":"1994","journal-title":"Anticancer. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"41734","DOI":"10.1074\/jbc.M307152200","article-title":"Aurintricarboxylic acid blocks in vitro and in vivo activity of YopH, an essential virulent factor of Yersinia pestis, the agent of plague","volume":"278","author":"Liang","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1073\/pnas.86.9.3322","article-title":"Specific interaction of aurintricarboxylic acid with the human immunodeficiency virus\/CD4 cell receptor","volume":"86","author":"Schols","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.antiviral.2008.10.006","article-title":"Aurintricarboxylic acid inhibits influenza virus neuraminidase","volume":"81","author":"Hung","year":"2009","journal-title":"Antiviral. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3389\/fmicb.2019.00718","article-title":"Potent Inhibition of Zika Virus Replication by Aurintricarboxylic Acid","volume":"10","author":"Park","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.1039\/c2ob25830g","article-title":"Pyridostatin analogues promote telomere dysfunction and long-term growth inhibition in human cancer cells","volume":"10","author":"Muller","year":"2012","journal-title":"Org. Biomol. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Ida, J., Chan, S.K., Glokler, J., Lim, Y.Y., Choong, Y.S., and Lim, T.S. (2019). G-Quadruplexes as An Alternative Recognition Element in Disease-Related Target Sensing. Molecules, 24.","DOI":"10.3390\/molecules24061079"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"7213","DOI":"10.1016\/j.vaccine.2017.11.015","article-title":"An in vitro cell-based potency assay for pharmaceutical type A botulinum antitoxins","volume":"35","author":"Torgeman","year":"2017","journal-title":"Vaccine"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1073\/pnas.0611213104","article-title":"An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists","volume":"104","author":"Eubanks","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"5226","DOI":"10.1091\/mbc.e08-07-0765","article-title":"Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons","volume":"19","author":"Dong","year":"2008","journal-title":"Mol. Biol. Cell."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.biologicals.2005.11.009","article-title":"A review of WHO International Standards for botulinum antitoxins","volume":"34","author":"Jones","year":"2006","journal-title":"Biologicals"},{"key":"ref_46","unstructured":"European Directorate for the Quality of Medicines and Healthcare (2014). Botulinum antitoxin. European Pharmacopoeia, EDQM Council of Europe."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1128\/CVI.00268-13","article-title":"The receptor binding domain of botulinum neurotoxin serotype A (BoNT\/A) inhibits BoNT\/A and BoNT\/E intoxications in vivo","volume":"20","author":"Diamant","year":"2013","journal-title":"Clin. Vaccine. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Diamant, E., Lachmi, B.E., Keren, A., Barnea, A., Marcus, H., Cohen, S., David, A.B., and Zichel, R. (2014). Evaluating the synergistic neutralizing effect of anti-botulinum oligoclonal antibody preparations. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0087089"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/16\/8577\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:43:06Z","timestamp":1760164986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/16\/8577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,9]]},"references-count":48,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["ijms22168577"],"URL":"https:\/\/doi.org\/10.3390\/ijms22168577","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,9]]}}}